Exiger Wins Government-Wide $919 Million GSA Supply Chain Risk Illumination Award

A Bitter Pill: America’s Dangerous Dependence on China-Made Pharmaceuticals

April 16, 2025

White Paper

How Global Supply Chains, Strategic Rivals, and Quality Breakdowns Threaten U.S. Healthcare

Exiger’s latest analysis using our expansive supply chain visibility AI, A Bitter Pill: America's Dangerous Dependence on China-Made Pharmaceuticals, exposes the vulnerabilities within America's healthcare supply chain, highlighting insights that are critical for national health security.

The release of A Bitter Pill is strategically timed with the congressional release of the National Security Commission on Emerging Biotechnology (NSCEB) report that emphasizes restoring U.S. manufacturing, addressing supply chain dependencies on China, and enhancing national security through biotechnology leadership.

NSCEB’s recommendations to secure America’s biotechnology future are substantiated by the Exiger report’s critical proprietary data that identifies significant U.S. pharmaceutical supply chain vulnerabilities.

The report advocates for increased transparency within the pharmaceutical supply chain, strategic national stockpiling, advanced research pathways, diversification of sourcing, and the revitalization of domestic manufacturing to safeguard public health and national security to ensure a healthy America.

As seen on FOX Business: Supply chain AI company sounds the alarm over America’s reliance on Chinese-made pharmaceuticals

A Bitter Pill reveals:

Immediate policy recommendations to mitigate these risks and ensure a resilient and ethical pharmaceutical supply for the nation
Nearly 90% of U.S. antibiotics rely on Chinese-made active pharmaceutical ingredients (APIs)
Heavy dependence on foreign suppliers increases risk of strategic withholding or supply chain sabotage during geopolitical conflict
Forced labor in regions like Xinjiang linked to pharmaceutical production
Quality and safety concerns tied to overseas manufacturing standards
Urgent need for greater supply chain transparency, diversified sourcing, and U.S.-based production

Download the report to uncover the urgent actions needed to stockpile critical medicines, boost domestic production, and eliminate forced labor from America’s drug supply.